New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
09:25 EDTNVO, NVONovo Nordisk to host conference call
Management holds a conference call on the haemophilia market and outlook, as well as on Novo Nordisk’s portfolio of haemophilia products, on May 27 at 9:30 am. Webcast Link
News For NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
12:50 EDTNVONovo Nordisk to launch Novoeight in U.S. for people with Hemophilia A
Novo Nordisk announced the company will launch Novoeight in the United States for people living with hemophilia A. Novoeight offers purity, reliability, and enhanced portability, with the highest storage temperature for the longest period of time compared with other marketed recombinant Factor VIII products—up to 86 degrees F for 12 months. It can be kept at that temperature for up to 4 hours after reconstitution, giving it the longest postreconstitution storage time. Novoeight offers purity through a 5-step purification process. It was shown to be safe and effective in clinical trials with zero inhibitors confirmed in 213 previously treated patients with hemophilia A. Novo Nordisk plans to make Novoeight available by mid-April.
12:35 EDTNVONovo Nordisk up almost 5%, near highs of session
Subscribe for More Information
12:26 EDTNVONovo Nordisk to resubmit NDAs of Tresiba, Ryzodeg in U.S.
Subscribe for More Information
11:13 EDTNVOBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 25, 2015
13:22 EDTNVONovo Nordisk says 3a trials achieved primary objectives
Novo Nordisk announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset 1 and onset 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively. Both trials achieved their primary objectives by demonstrating that treatment with faster-acting insulin aspart is non-inferior to NovoRapid with regard to lowering of HbA1c. For people with type 1 diabetes, the HbA1c lowering achieved with faster-acting insulin aspart was statistically significantly larger than that achieved with NovoRapid when the insulins were given at mealtime. In addition, treatment with faster-acting insulin aspart was associated with less increase of postprandial glucose than NovoRapid during meal tests in both trials. In both trials, the previously reported safety and tolerability profiles of faster-acting insulin aspart and NovoRapid were confirmed, and there were no apparent differences between the two treatment groups with respect to adverse events and other safety parameters, Novo said.
10:03 EDTNVOHigh option volume stocks
High option volume stocks: NVO SXC SONC EXH KRFT WLB ETR LXK APOL EWH
March 24, 2015
10:09 EDTNVOHigh option volume stocks
Subscribe for More Information
08:02 EDTNVOBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
March 23, 2015
09:45 EDTNVOUBS to hold a field trip
Subscribe for More Information
March 22, 2015
12:16 EDTNVONovo Nordisk to hold a conference call
Subscribe for More Information
March 19, 2015
11:07 EDTNVONovo Nordisk management to meet with Jefferies
Meeting to be held in Connecticut on March 24 hosted by Jefferies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use